Aclaris Therapeutics, Inc.
ACRS
$2.83
-$0.05-1.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 85.65% | 22.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 85.65% | 22.13% | |||
| Cost of Revenue | -81.59% | 1.52% | |||
| Gross Profit | 107.38% | 1.06% | |||
| SG&A Expenses | -9.56% | -12.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.90% | -2.88% | |||
| Operating Income | -0.83% | 4.93% | |||
| Income Before Tax | 5.28% | -2.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.28% | -2.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.28% | -2.28% | |||
| EBIT | -0.83% | 4.93% | |||
| EBITDA | -0.94% | 4.93% | |||
| EPS Basic | 5.32% | -2.11% | |||
| Normalized Basic EPS | -4.23% | 5.96% | |||
| EPS Diluted | 5.32% | -2.11% | |||
| Normalized Diluted EPS | -4.23% | 5.96% | |||
| Average Basic Shares Outstanding | 0.03% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||